3 май 2016 г. - FDA convened a joint meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee to discuss results from assessments of the extended-release and long- acting (ER/LA) Opioid Analgesics Risk Evaluation and Mitigation Strategies (REMS)
Добавлено на ленту времени:
Дата:
3 май 2016 г.
Сейчас
~ 9 гг и 5 мес назад